Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company’s chairman of the board Bert Junno increases his holding in Cyxone by exercise of 100 000 warrants.
Bert Junno, chairman of the board for Cyxone, commented: “Cyxone is currently in a very eventful phase with several milestones on the horizon. The success that the candidates, T20K and Rabeximod, have been able to show so far has made me more convinced of the potential of Cyxone. I see a very bright future for the company, which is why I now choose to expand my private holdings.”
Chairman of the board